[{"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.", "fullTimeEmployees": 609, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher R. Anzalone Ph.D.", "age": 55, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 2104473, "exercisedValue": 1024000, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  O'Brien J.D., PharmD", "age": 60, "title": "COO, General Counsel & Secretary", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 998520, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James C. Hamilton M.D., MBA", "age": 46, "title": "Chief Medical Officer and Head of R&D", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 897694, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark M. Davis Ph.D.", "title": "Founder and Founder & Director of Insert Therapeutics Inc & Calando", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel J. Apel", "title": "Chief Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Lovy", "title": "Director of Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruce D. Given M.D.", "age": 70, "title": "Chief Medical Scientist", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 486308, "exercisedValue": 5934362, "unexercisedValue": 6159876}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 70, "title": "Head of Toxicology & VP", "yearBorn": 1954, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Aaron  Tan", "title": "Head of Tax", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 2, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.arrowheadresearch.com/invest.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 42.31, "open": 42.32, "dayLow": 41.31, "dayHigh": 43.69, "regularMarketPreviousClose": 42.31, "regularMarketOpen": 42.32, "regularMarketDayLow": 41.31, "regularMarketDayHigh": 43.69, "payoutRatio": 0.0, "beta": 1.137, "forwardPE": -10.045024, "volume": 1676214, "regularMarketVolume": 1673629, "averageVolume": 2376871, "averageVolume10days": 1646690, "averageDailyVolume10Day": 1646690, "bid": 34.55, "ask": 53.12, "bidSize": 2, "askSize": 2, "marketCap": 5860737536, "fiftyTwoWeekLow": 9.57, "fiftyTwoWeekHigh": 43.69, "allTimeHigh": 2925.0, "allTimeLow": 1.2, "priceToSalesTrailing12Months": 10.228592, "fiftyDayAverage": 32.6111, "twoHundredDayAverage": 20.412874, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5673344512, "profitMargins": -0.25902998, "floatShares": 119533330, "sharesOutstanding": 138257550, "sharesShort": 11648427, "sharesShortPriorMonth": 11862693, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.084300004, "heldPercentInsiders": 0.04407, "heldPercentInstitutions": 0.78287005, "shortRatio": 5.36, "shortPercentOfFloat": 0.1087, "impliedSharesOutstanding": 138257550, "bookValue": 3.781, "priceToBook": 11.21132, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -148416992, "trailingEps": -1.2, "forwardEps": -4.22, "lastSplitFactor": "1:10", "lastSplitDate": 1321488000, "enterpriseToRevenue": 9.902, "enterpriseToEbitda": -66.436, "52WeekChange": 1.1131606, "SandP52WeekChange": 0.19736934, "quoteType": "EQUITY", "currentPrice": 42.39, "targetHighPrice": 80.0, "targetLowPrice": 17.0, "targetMeanPrice": 47.5, "targetMedianPrice": 45.0, "recommendationMean": 1.84615, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 898172032, "totalCashPerShare": 6.496, "ebitda": -85396000, "totalDebt": 713286016, "quickRatio": 4.667, "currentRatio": 4.868, "totalRevenue": 572976000, "debtToEquity": 137.222, "revenuePerShare": 4.395, "returnOnAssets": -0.0596, "returnOnEquity": -0.37111, "grossProfits": 572976000, "freeCashflow": -48370124, "operatingCashflow": 21845000, "grossMargins": 1.0, "ebitdaMargins": -0.14904, "operatingMargins": -5.96211, "financialCurrency": "USD", "symbol": "ARWR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": 0.189076, "regularMarketPrice": 42.39, "shortName": "Arrowhead Pharmaceuticals, Inc.", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 756052200000, "postMarketChangePercent": 0.6841258, "postMarketPrice": 42.68, "postMarketChange": 0.29000092, "regularMarketChange": 0.079998, "regularMarketDayRange": "41.31 - 43.69", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2376871, "fiftyTwoWeekLowChange": 32.82, "fiftyTwoWeekLowChangePercent": 3.4294672, "fiftyTwoWeekRange": "9.57 - 43.69", "fiftyTwoWeekHighChange": -1.2999992, "fiftyTwoWeekHighChangePercent": -0.029755076, "fiftyTwoWeekChangePercent": 111.31606, "earningsTimestamp": 1754596800, "earningsTimestampStart": 1764187200, "earningsTimestampEnd": 1764187200, "earningsCallTimestampStart": 1754598600, "earningsCallTimestampEnd": 1754598600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -1.2, "epsForward": -4.22, "epsCurrentYear": -0.27909, "priceEpsCurrentYear": -151.88649, "longName": "Arrowhead Pharmaceuticals, Inc.", "cryptoTradeable": false, "fiftyDayAverageChange": 9.7789, "fiftyDayAverageChangePercent": 0.29986417, "twoHundredDayAverageChange": 21.977125, "twoHundredDayAverageChangePercent": 1.0766306, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "corporateActions": [], "postMarketTime": 1761946737, "regularMarketTime": 1761940802, "exchange": "NMS", "messageBoardId": "finmb_203142", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Arrowhead Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-11-01"}]